Biogen and Eisai release new Alzheimer’s drug data that may support wider uptake
October 25, 2023 at 17:28 PM EDT
Eisai plans to apply for FDA approval of subcutaneous Leqembi by early next year.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.